Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study

Podobne zapisy

• Correction to: Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study
  od: Naganuma, Makoto, i wsp.
  Wydane: (2017)
• Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis
  od: Naganuma, Makoto, i wsp.
  Wydane: (2016)
• Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foam
  od: Naganuma, Makoto, i wsp.
  Wydane: (2019)
• Predictive factors for achievement of mucosal healing by budesonide 2-mg foam in ulcerative colitis: a pooled analysis of data from two clinical trials
  od: Hibi, Toshifumi, i wsp.
  Wydane: (2020)
• First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis
  od: Kobayashi, Taku, i wsp.
  Wydane: (2015)